Similarly, if separate osteolytic effects of tumoral ERα signaling are also demonstrated to drive ER+ BMET progression, novel molecular approaches targeting specific tumoral osteolytic pathways downstream of ERα could provide new avenues for skeletal therapeutics to block BMET progression for ER+ tumors, which comprise the majority of breast cancer BMET. Here, ESR1 is linked to breast cancer.